CL2025001070A1 - Compuestos, composiciones y métodos - Google Patents

Compuestos, composiciones y métodos

Info

Publication number
CL2025001070A1
CL2025001070A1 CL2025001070A CL2025001070A CL2025001070A1 CL 2025001070 A1 CL2025001070 A1 CL 2025001070A1 CL 2025001070 A CL2025001070 A CL 2025001070A CL 2025001070 A CL2025001070 A CL 2025001070A CL 2025001070 A1 CL2025001070 A1 CL 2025001070A1
Authority
CL
Chile
Prior art keywords
compounds
compositions
methods
acds
antibody
Prior art date
Application number
CL2025001070A
Other languages
English (en)
Inventor
Li Runsheng
Huang Wentao
Liu Zhifang
Qin ZANG Ying
Original Assignee
Lanova Medicines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanova Medicines Ltd filed Critical Lanova Medicines Ltd
Publication of CL2025001070A1 publication Critical patent/CL2025001070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a los compuestos anticancerosos, incluidos, entre otros, los conjugados anticuerpo-fármaco que utilizan los mismos, qué compuestos y ACD de los mismos son adecuados para el tratamiento del cáncer.
CL2025001070A 2022-10-09 2025-04-09 Compuestos, composiciones y métodos CL2025001070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022124073 2022-10-09

Publications (1)

Publication Number Publication Date
CL2025001070A1 true CL2025001070A1 (es) 2025-07-25

Family

ID=90668766

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001070A CL2025001070A1 (es) 2022-10-09 2025-04-09 Compuestos, composiciones y métodos

Country Status (12)

Country Link
US (2) US12291537B2 (es)
EP (1) EP4598929A1 (es)
JP (1) JP2025533191A (es)
KR (1) KR20250079213A (es)
CN (1) CN120379997A (es)
AU (1) AU2023359114A1 (es)
CL (1) CL2025001070A1 (es)
CO (1) CO2025005954A2 (es)
IL (1) IL320161A (es)
MX (1) MX2025004219A (es)
PE (1) PE20252282A1 (es)
WO (1) WO2024078449A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
AP9300587A0 (en) 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US6177439B1 (en) 1995-06-06 2001-01-23 Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6288072B1 (en) 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
US6825206B1 (en) 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US7067666B2 (en) 2003-06-27 2006-06-27 Research Triangle Institute 7-substituted camptothecin and camptothecin analogs and methods for producing the same
US20080039485A1 (en) 2006-08-08 2008-02-14 Targetgen Biotechnology Co., Ltd. Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers
US20140073778A9 (en) 2010-07-09 2014-03-13 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
CA2850955C (en) 2011-11-03 2019-11-19 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
CN103289461B (zh) 2013-07-01 2016-05-04 厦门大学 喜树碱及其衍生物作为防污剂的应用
US20160375042A1 (en) 2014-01-28 2016-12-29 Wenqiang Zhou Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma
CN106715443A (zh) 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途
EP3130608B1 (en) * 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
JP6948708B2 (ja) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
CA3074208C (en) * 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
JP2021095424A (ja) 2018-03-28 2021-06-24 持田製薬株式会社 抗癌剤結合アルギン酸誘導体
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110590796B (zh) 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
JP2022501432A (ja) 2018-09-17 2022-01-06 キャンゲット バイオテクファーマ， エルエルシー ヒト疾患の治療のためのｆｌ１１８プラットフォーム位置７および９由来の類似体の組成、合成、処方および適用の問題
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
US20230072897A1 (en) 2019-06-06 2023-03-09 Shanghai Hansoh Biomedical Co., Ltd. Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
PH12021500050A1 (en) 2019-06-24 2022-05-02 Hangzhou Dac Biotech Co Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
EP4038101A2 (en) 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
EP4096717B1 (en) * 2020-01-31 2024-12-11 Innate Pharma Treatment of cancer
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
BR112022025583A2 (pt) 2020-06-19 2023-01-03 Hangzhou Dac Biotech Co Ltd Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
EP4178559A4 (en) 2020-07-10 2025-03-05 Velosbio Inc. Novel ror1 antibody immunoconjugates
BR112023004415A2 (pt) 2020-09-11 2023-05-09 Medimmune Ltd Moléculas terapêuticas de ligação a b7-h4
JP2023551355A (ja) * 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド 抗腫瘍化合物並びにその調製方法及び使用
JP7753372B2 (ja) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
WO2022078279A1 (zh) 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
MX2023005873A (es) * 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
EP4628165A3 (en) 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
GEAP202416409A (en) * 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
EP4460330A1 (en) * 2022-01-06 2024-11-13 Virtuoso Binco, Inc. Conjugates, compositions and methods of use
TW202341984A (zh) * 2022-01-28 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Ｈｅｒ３抗體藥物偶聯物及其用途
KR20240163098A (ko) * 2022-03-30 2024-11-18 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 B7h4 항체-약물 접합체 및 이의 용도

Also Published As

Publication number Publication date
WO2024078449A1 (en) 2024-04-18
JP2025533191A (ja) 2025-10-03
US20240262841A1 (en) 2024-08-08
MX2025004219A (es) 2025-07-01
CO2025005954A2 (es) 2025-07-28
AU2023359114A1 (en) 2025-04-24
US12291537B2 (en) 2025-05-06
KR20250079213A (ko) 2025-06-04
CN120379997A (zh) 2025-07-25
IL320161A (en) 2025-06-01
US20250270228A1 (en) 2025-08-28
PE20252282A1 (es) 2025-09-18
EP4598929A1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CL2022002828A1 (es) Inhibidores de kras tricíclicos fusionados.
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
MX2019007471A (es) Composiciones y métodos para inhibir la actividad de la arginasa.
UY38476A (es) Inhibidores de arg1 y/o arg2
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2025005954A2 (es) Compuestos, composiciones y métodos
CL2024000560A1 (es) Inhibidores de indolina de kif18a
MX2024007938A (es) Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead.
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
CL2022000043A1 (es) Conjugados peptídicos de agentes dirigidos a los microtúbulos como terapéuticos.
DOP2024000102A (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
MX2018013519A (es) Inhibidores del potenciador del homologo zeste 2.
CO2022014837A2 (es) Células t v delta1+ para el tratamiento de neoplasias mieloides
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
DOP2022000127A (es) Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos.
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
ECSP23044970A (es) Compuestos y composiciones de moléculas pequeñas
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
CO2020000617A2 (es) Novedosos compuestos que activan la ruta nrf2